Sunday, June 22, 2014 10:23:53 PM
http://www.lctglobal.com/upload/news/pdfs/140623%20LCT%20Parkinsons%20trial%20resumes%20patient%20recruitment.pdf
Living Cell Technologies Limited has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.
Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.
“The completion of the clinical trial is an initial step in progressing NTCELL to commercialization as the first disease modifying treatment for Parkinson’s disease.”
Read the full announcement here.
Never buy/sell based on my posts.My posts are opinions
only.My positions are subject to change W/O
notice NOTICE: NSA reportedly monitors,copies,and
captures IP address of electronic communications to and from the USA.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM